| Year |
Citation |
Score |
| 2020 |
Al-Katib AM, Ebrahim AS, Kandouz M, Zaiem F, Raufi A, Ebrahim S, Mohamed A, Emara N, Gabali AM. Isolation and characterization of a CD34 sub-clone in B-cell lymphoma. Oncotarget. 11: 148-160. PMID 32010428 DOI: 10.18632/Oncotarget.27415 |
0.397 |
|
| 2019 |
Rezvani S, Tominna M, Al-Katib S, Smith MD, Cousineau C, Al-Katib A. Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates. Case Reports in Pulmonology. 2019: 9870494. PMID 30805241 DOI: 10.1155/2019/9870494 |
0.303 |
|
| 2019 |
Al-Katib A, Kuzel TM, Parchment R. A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma Blood. 134: 4041-4041. DOI: 10.1182/Blood-2019-127278 |
0.382 |
|
| 2017 |
Ebrahim AS, Kandouz M, Emara N, Sugalski AB, Lipovich L, Al-Katib AM. Unintended target effect of anti-BCL-2 DNAi. Cancer Management and Research. 9: 427-432. PMID 28989285 DOI: 10.2147/Cmar.S139105 |
0.451 |
|
| 2017 |
Khan U, Hadid T, Ibrar W, Sano D, Al-Katib A. Composite Lymphoma: Opposite Ends of Spectrum Meet. Journal of Clinical Medicine Research. 9: 213-215. PMID 28179969 DOI: 10.14740/Jocmr2929W |
0.348 |
|
| 2016 |
Singh B, Ip R, Ibrahim Al-Rajjal A, Kafri Z, Al-Katib A, Hadid T. Primary Cardiac Lymphoma: Lessons Learned from a Long Survivor. Case Reports in Cardiology. 2016: 7164829. PMID 28053792 DOI: 10.1155/2016/7164829 |
0.321 |
|
| 2016 |
Shukkur Ebrahim A, Kandouz M, Liddane A, Sabbagh H, Hou Y, Li C, Al-Katib A. PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma. Oncotarget. PMID 27283896 DOI: 10.18632/Oncotarget.9872 |
0.512 |
|
| 2016 |
Ebrahim AS, Sabbagh H, Liddane A, Raufi A, Kandouz M, Al-Katib A. Hematologic malignancies: newer strategies to counter the BCL-2 protein. Journal of Cancer Research and Clinical Oncology. 142: 2013-22. PMID 27043233 DOI: 10.1007/S00432-016-2144-1 |
0.377 |
|
| 2014 |
Al-Katib AM, Aboukameel A, Ebrahim A, Beck FW, Tekyi-Mensah SE, Raufi A, Ahmed Y, Mandziara M, Kafri Z. Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3β) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. Experimental Hematology & Oncology. 3: 31. PMID 25937997 DOI: 10.1186/2162-3619-3-31 |
0.368 |
|
| 2014 |
Shalhout S, Haddad D, Sosin A, Holland TC, Al-Katib A, Martin A, Bhagwat AS. Genomic uracil homeostasis during normal B cell maturation and loss of this balance during B cell cancer development. Molecular and Cellular Biology. 34: 4019-32. PMID 25154417 DOI: 10.1128/Mcb.00589-14 |
0.745 |
|
| 2014 |
Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, ... ... Al-Katib A, et al. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemotherapy and Pharmacology. 74: 151-66. PMID 24832107 DOI: 10.1007/S00280-014-2476-Y |
0.366 |
|
| 2014 |
Woolliscroft MJ, Ebrahim A, Messmann RA, Gaylor SK, Sooch MP, Al-Katib A, Rodrigueza WV. Abstract 5473: The sensitivity of targeting genomic BCL2 by PNT2258 is linked to chromosomal rearrangements and proliferative rate of tumor types Cancer Research. 74: 5473-5473. DOI: 10.1158/1538-7445.Am2014-5473 |
0.479 |
|
| 2013 |
Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419 Cancer Management and Research. 5: 225-233. PMID 24023523 DOI: 10.2147/Cmar.S45957 |
0.388 |
|
| 2013 |
Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica. 98: 1098-106. PMID 23403316 DOI: 10.3324/Haematol.2012.074781 |
0.407 |
|
| 2013 |
Harb WA, Lakhani N, Logsdon A, Steigelman M, Smith-Green H, Gaylor S, Rodrigueza W, Woolliscroft M, Sooch M, Messmann RA, Al-Katib A. The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma Blood. 122: 88-88. DOI: 10.1182/Blood.V124.21.1716.1716 |
0.415 |
|
| 2012 |
Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. Journal of Hematology & Oncology. 5: 57. PMID 22989009 DOI: 10.1186/1756-8722-5-57 |
0.772 |
|
| 2012 |
Obeid KM, Aguilar J, Szpunar S, Sharma M, del Busto R, Al-Katib A, Johnson LB. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clinical Lymphoma, Myeloma & Leukemia. 12: 66-9. PMID 22000698 DOI: 10.1016/J.Clml.2011.07.006 |
0.339 |
|
| 2011 |
Sosin AM, Yang D, Mohammad RM, Al-Katib A. Abstract 594: MDM2 inhibition by MI-219 elicits differential molecular effects in wild-type p53 lymphoma cells Cancer Research. 71: 594-594. DOI: 10.1158/1538-7445.Am2011-594 |
0.769 |
|
| 2010 |
Al-Katib A, Arnold AA, Aboukameel A, Sosin A, Smith P, Mohamed AN, Beck FW, Mohammad RM. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. Molecular Cancer. 9: 228. PMID 20809973 DOI: 10.1186/1476-4598-9-228 |
0.76 |
|
| 2010 |
Sosin AM, Burger AM, Yang D, Mohammad RM, Al-Katib A. Abstract 4516: A new class of MDM2 inhibitors cause growth inhibition and stabilize wt p53 in lymphoma cells but do not interfere with MDM2 E3 ligase activity Cancer Research. 70: 4516-4516. DOI: 10.1158/1538-7445.Am10-4516 |
0.761 |
|
| 2009 |
Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Molecular Cancer. 8: 115. PMID 19958544 DOI: 10.1186/1476-4598-8-115 |
0.774 |
|
| 2009 |
Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4038-45. PMID 19509168 DOI: 10.1158/1078-0432.Ccr-08-2808 |
0.337 |
|
| 2009 |
Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, Mohammad RM. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. Journal of Hematology & Oncology. 2: 8. PMID 19220884 DOI: 10.1186/1756-8722-2-8 |
0.492 |
|
| 2008 |
Sun Y, Wu J, Aboukameel A, Banerjee S, Arnold AA, Chen J, Nikolovska-Coleska Z, Lin Y, Ling X, Yang D, Wang S, Al-Katib A, Mohammad RM. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biology & Therapy. 7: 1418-26. PMID 18769131 DOI: 10.4161/Cbt.7.9.6430 |
0.487 |
|
| 2008 |
Arnold AA, Aboukameel A, Chen J, Yang D, Wang S, Al-Katib A, Mohammad RM. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model. Molecular Cancer. 7: 20. PMID 18275607 DOI: 10.1186/1476-4598-7-20 |
0.508 |
|
| 2007 |
Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2226-35. PMID 17404107 DOI: 10.1158/1078-0432.Ccr-06-1574 |
0.494 |
|
| 2007 |
Mohammad RM, Sun Y, Wang S, Aboukameel A, Al-Katib AM. Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples. Blood. 110: 4521-4521. DOI: 10.1182/Blood.V110.11.4521.4521 |
0.52 |
|
| 2007 |
Aboukameel A, Goustin A, Mohammad R, Zuany-Amorim C, Bissery M, Al-Katib AM. Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation. Blood. 110: 2339-2339. DOI: 10.1182/Blood.V110.11.2339.2339 |
0.387 |
|
| 2007 |
Goustin A, Giri A, Wang S, Al-Katib A, Ramzi MM. Surface Plasmon Resonance Study of Apoptotic Regulators Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 Indicate That the Preclinical Small Molecule Inhibitor (SMI) TW-37 Binds to the Hydrophobic Groove Competitively with tBid To Form a Heterodimer Which Cannot Be Disrupted by 200-Fold Molar Excess of TW-37. Blood. 110: 1606-1606. DOI: 10.1182/Blood.V110.11.1606.1606 |
0.328 |
|
| 2005 |
Jenkins BD, Snower D, Mohamed A, Al-Katib A. Variant lymphoproliferative disorder of granular lymphocytes (LDGL) following Hodgkin lymphoma American Journal of Hematology. 79: 128-131. PMID 15929104 DOI: 10.1002/Ajh.20312 |
0.322 |
|
| 2005 |
Hamdy N, Goustin AS, Desaulniers JP, Li M, Chow CS, Al-Katib A. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. Journal of Immunological Methods. 297: 109-24. PMID 15777935 DOI: 10.1016/J.Jim.2004.12.003 |
0.341 |
|
| 2005 |
Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Molecular Cancer Therapeutics. 4: 13-21. PMID 15657349 |
0.368 |
|
| 2005 |
Mohamed AN, Bentley G, Bonnett ML, Palutke M, Al-Katib AM. Cytogenetic Abnormalities in Histologically Confirmed Multiple Myeloma. Blood. 106: 5082-5082. DOI: 10.1182/Blood.V106.11.5082.5082 |
0.302 |
|
| 2004 |
Al-Katib AM, Aboukameel A, Beck F, Mohammad R. Synergistic interaction between rituximab and 2-chlorodeoxyadenosine (2-CdA) against Waldenstrom's Macroglobulinemia preclinical model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2529. PMID 28015012 DOI: 10.1200/Jco.2004.22.14_Suppl.2529 |
0.412 |
|
| 2004 |
Beck FW, Eilender DS, Dandashi MH, Siddiq F, Snell DC, Godmere MA, Al-Katib AM, Mohammad RM. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. International Journal of Molecular Medicine. 14: 113-9. PMID 15202025 DOI: 10.3892/Ijmm.14.1.113 |
0.311 |
|
| 2004 |
Mensah-Osman E, Al-Katib A, Dandashi M, Mohammad R. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. International Journal of Oncology. 23: 1637-44. PMID 14612935 |
0.373 |
|
| 2003 |
Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Molecular Cancer Therapeutics. 2: 1361-8. PMID 14707277 |
0.377 |
|
| 2003 |
Al-Katib AM, Mensah-Osman E, Aboukameel A, Mohammad R. The Wayne State University Waldenstrom's Macroglobulinemia preclinical model for Waldenstrom's macroglobulinemia. Seminars in Oncology. 30: 313-7. PMID 12720160 DOI: 10.1053/Sonc.2003.50043 |
0.393 |
|
| 2003 |
Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, Miguel JFS, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia Seminars in Oncology. 30: 110-115. PMID 12720118 DOI: 10.1053/Sonc.2003.50082 |
0.309 |
|
| 2002 |
Mensah-Osman EJ, Al-Katib AM, Wu HY, Osman NI, Mohammad RM. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity. Molecular Cancer Therapeutics. 1: 1321-6. PMID 12516965 |
0.355 |
|
| 2002 |
Mensah-Osman EJ, Al-Katib AM, Dandashi MH, Mohammad RM. 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model. Molecular Cancer Therapeutics. 1: 1315-20. PMID 12516964 |
0.366 |
|
| 2002 |
Mohammad RM, Aboukameel A, Nabha S, Ibrahim D, Al-Katib A. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient. Journal of Drug Targeting. 10: 405-10. PMID 12442811 DOI: 10.1080/1061186021000001850 |
0.378 |
|
| 2002 |
Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2735-41. PMID 12171907 |
0.394 |
|
| 2002 |
Vaishampayan U, Karanes C, Du W, Varterasian M, Al-Katib A. Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation. Cancer Investigation. 20: 303-310. PMID 12025224 DOI: 10.1081/Cnv-120001174 |
0.316 |
|
| 2002 |
Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1277-83. PMID 11948143 |
0.349 |
|
| 2002 |
Varterasian ML, Pemberton PA, Hulburd K, Rodriguez DH, Murgo A, Al-Katib AM. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Investigational New Drugs. 19: 245-7. PMID 11561682 DOI: 10.1023/A:1010676719178 |
0.326 |
|
| 2001 |
Wall NR, Beck FWJ, Al-Katib AM, Mohammad RM. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line Journal of Drug Targeting. 9: 329-339. PMID 11770703 DOI: 10.3109/10611860108998769 |
0.435 |
|
| 2001 |
Mohamed AN, Palutke M, Eisenberg L, Al-Katib A. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genetics and Cytogenetics. 126: 45-51. PMID 11343778 DOI: 10.1016/S0165-4608(00)00383-6 |
0.322 |
|
| 2001 |
Nabha SM, Mohammad RM, Wall NR, Dutcher JA, Salkini BM, Pettit GR, Al-Katib AM. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: Preclinical efficacy Anti-Cancer Drugs. 12: 57-63. PMID 11272287 DOI: 10.1097/00001813-200101000-00008 |
0.418 |
|
| 2000 |
Nabha SM, Wall NR, Mohammad RM, Pettit GR, Al-Katib AM. Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines Anti-Cancer Drugs. 11: 385-392. PMID 10912955 DOI: 10.1097/00001813-200006000-00009 |
0.4 |
|
| 2000 |
Beck FW, Al-Katib AM, Ahmad I, Wall NR, Liu KZ, Mantsch HH, Mohammad RM. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. International Journal of Molecular Medicine. 5: 341-347. PMID 10719048 DOI: 10.3892/Ijmm.5.4.341 |
0.411 |
|
| 2000 |
Wall NR, Mohammad RM, Reddy KB, Al-Katib AM. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh. International Journal of Molecular Medicine. 5: 165-171. PMID 10639596 DOI: 10.3892/Ijmm.5.2.165 |
0.42 |
|
| 1999 |
Wall NR, Mohammad RM, Nabha SM, Pettit GR, Al-Katib AM. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh Biochemical and Biophysical Research Communications. 266: 76-80. PMID 10581168 DOI: 10.1006/Bbrc.1999.1768 |
0.449 |
|
| 1999 |
Wall NR, Mohammad RM, Al-Katib AM. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh Leukemia Research. 23: 881-888. PMID 10573132 DOI: 10.1016/S0145-2126(99)00108-3 |
0.403 |
|
| 1999 |
Aref A, Yudelev M, Mohammad R, Choudhuri R, Orton C, Al-Katib A. Neutron and photon clonogenic survival curves of two chemotherapy resistant human intermediate-grade non-Hodgkin lymphoma cell lines. International Journal of Radiation Oncology, Biology, Physics. 45: 999-1003. PMID 10571208 DOI: 10.1016/S0360-3016(99)00258-8 |
0.397 |
|
| 1999 |
Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsay V, Vaitkevicius VK, Al-Katib AM, Sarkar FH. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma Pancreas. 19: 353-361. PMID 10547195 DOI: 10.1097/00006676-199911000-00006 |
0.452 |
|
| 1999 |
Liu KZ, Schultz CP, Johnston JB, Beck FW, Al-Katib AM, Mohammad RM, Mantsch HH. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line. Leukemia. 13: 1273-80. PMID 10450757 DOI: 10.1038/Sj.Leu.2401463 |
0.333 |
|
| 1999 |
Mohammad RM, Limvarapuss C, Wall NR, Hamdy N, Beck FW, Pettit GR, Al-Katib A. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model. International Journal of Oncology. 15: 367-372. PMID 10402249 DOI: 10.3892/Ijo.15.2.367 |
0.465 |
|
| 1999 |
Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FWJ, Wall NR, Al-Katib AM. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine International Journal of Oncology. 14: 945-950. PMID 10200346 DOI: 10.3892/Ijo.14.5.945 |
0.442 |
|
| 1999 |
Zheng G, Wu K, Geng Y, Kong J, Al-Katib A, Dan M, Chen B. Expression of membrane-associated macrophage colony-stimulating factor (M-CSF) in Hodgkin's disease and other hematologic malignancies. Leukemia & Lymphoma. 32: 339-344. PMID 10037031 DOI: 10.3109/10428199909167394 |
0.301 |
|
| 1998 |
Liu KZ, Schultz CP, Mohammad RM, Al-Katib AM, Johnston JB, Mantsch HH. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study. Cancer Letters. 127: 185-93. PMID 9619876 DOI: 10.1016/S0304-3835(98)00036-6 |
0.427 |
|
| 1998 |
Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M, Al-Katib A. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anti-Cancer Drugs. 9: 149-56. PMID 9510501 DOI: 10.1097/00001813-199802000-00006 |
0.446 |
|
| 1998 |
Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-Katib AM. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 56-62. PMID 9440723 DOI: 10.1200/Jco.1998.16.1.56 |
0.354 |
|
| 1997 |
Mohammad RM, Maki A, Pettit GR, al-Katib AM. Bryostatin 1 induces ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia cells. Enzyme & Protein. 49: 262-72. PMID 9252784 DOI: 10.1159/000468636 |
0.323 |
|
| 1997 |
Li Y, Mohammad RM, Al-Katib A, Varterasian ML, Chen B. Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. Leukemia Research. 21: 391-397. PMID 9225065 DOI: 10.1016/S0145-2126(96)00078-1 |
0.395 |
|
| 1997 |
König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E, Gabrilove JL. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 11: 258-65. PMID 9009090 DOI: 10.1038/Sj.Leu.2400556 |
0.509 |
|
| 1997 |
Maki A, Mohammad R, Raza S, Saleh M, Govindaraju KD, Pettit GR, al-Katib A. Effect of dolastatin 10 on human non-Hodgkin's lymphoma cell lines. Anti-Cancer Drugs. 7: 344-50. PMID 8792010 DOI: 10.1097/00001813-199605000-00016 |
0.479 |
|
| 1997 |
König A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL. The Novel Cyclin-Dependent Kinase Inhibitor Flavopiridol Downregulates Bcl-2 and Induces Growth Arrest and Apoptosis in Chronic B-Cell Leukemia Lines Blood. 90: 4307-4312. DOI: 10.1182/Blood.V90.11.4307.4307_4307_4312 |
0.529 |
|
| 1996 |
Maki A, Mohammad RM, Smith M, Al-Katib A. Role of ubiquitin carboxyl terminal hydrolase in the differentiation of human acute lymphoblastic leukemia cell line, Reh Differentiation. 60: 59-66. PMID 8935929 DOI: 10.1046/J.1432-0436.1996.6010059.X |
0.41 |
|
| 1996 |
Mohamed AN, Compean R, Dan ME, Smith MR, Al-Katib A. Clonal evolution of chronic lymphocytic leukemia to acute lymphoblastic leukemia Cancer Genetics and Cytogenetics. 86: 143-146. PMID 8603341 DOI: 10.1016/0165-4608(95)00202-2 |
0.36 |
|
| 1995 |
Varterasian M, Ratanatharathorn V, Uberti JP, Karanes C, Abella E, Momin F, Kasten-Sportes C, Al-Katib A, Lum L, Heilbrun LK, Sensenbrenner LL. Clinical Course and Outcome of Patients with Hodgkin's Disease who Progress after Autologous Transplantation Leukemia & Lymphoma. 20: 59-65. PMID 8750624 DOI: 10.3109/10428199509054754 |
0.324 |
|
| 1995 |
Mohammad RM, Vistisen K, al-Katib A. Protein study of T and B acute lymphoblastic leukemia cell lines. Electrophoresis. 15: 1218-24. PMID 7859731 DOI: 10.1002/Elps.11501501184 |
0.319 |
|
| 1995 |
Maki A, Diwakaran H, Redman B, al-Asfar S, Pettit GR, Mohammad RM, al-Katib A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anti-Cancer Drugs. 6: 392-7. PMID 7670136 DOI: 10.1097/00001813-199506000-00005 |
0.551 |
|
| 1995 |
Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, al-Katib A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Research. 19: 667-73. PMID 7564478 DOI: 10.1016/0145-2126(95)00037-O |
0.54 |
|
| 1993 |
Mohammad RM, al-Katib A, Pettit GR, Sensenbrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leukemia Research. 17: 1-8. PMID 8429674 DOI: 10.1016/0145-2126(93)90134-7 |
0.511 |
|
| 1993 |
al-Katib A, Mohammad RM, Khan K, Dan ME, Pettit GR, Sensenbrenner LL. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 33-42. PMID 8399068 DOI: 10.1097/00002371-199307000-00005 |
0.446 |
|
| 1993 |
Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genetics and Cytogenetics. 70: 62-67. PMID 8221615 DOI: 10.1016/0165-4608(93)90132-6 |
0.426 |
|
| 1993 |
Al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model Blood. 81: 3034-3042. DOI: 10.1182/Blood.V81.11.3034.Bloodjournal81113034 |
0.431 |
|
| 1992 |
Mohamed AN, Smith MR, Al-Katib A, Wolman SR. Emergence of myeloid stem cell line from T-lymphoid blastic phase of chronic myeloid leukemia in culture. Leukemia Research. 16: 521-527. PMID 1625478 DOI: 10.1016/0145-2126(92)90179-B |
0.376 |
|
| 1992 |
Mohammad RM, Mohamed AN, Kukuruga M, Smith MR, Al-Katib A. A human B-cell lymphoma line with a de novo multidrug resistance phenotype Cancer. 69: 1468-1474. PMID 1540884 DOI: 10.1002/1097-0142(19920315)69:6<1468::Aid-Cncr2820690626>3.0.Co;2-8 |
0.497 |
|
| 1991 |
Mohammad RM, Clark CR, Maloney TM, Chen BD, Al-Katib A. Expression of a New Cellular Protein by Monocytoid B-Lymphocytes Differentiated from the Acute Lymphoblastic Leukemia Cell Line (REH). Leukemia & Lymphoma. 4: 277-84. PMID 27463048 DOI: 10.3109/10428199109068077 |
0.464 |
|
| 1990 |
al-Katib A, Mohammad RM, Mohamed AN, Pettit GR, Sensenbrenner LL. Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematological Oncology. 8: 81-9. PMID 2344999 DOI: 10.1002/Hon.2900080203 |
0.425 |
|
| 1988 |
Mohamed AN, Al-Katib A. Establishment and characterization of a human lymphoma cell line (WSU-NHL) with 14;18 translocation Leukemia Research. 12: 833-843. PMID 3143865 DOI: 10.1016/0145-2126(88)90037-9 |
0.502 |
|
| Show low-probability matches. |